Newly Approved Antipsychotic Cobenfy Improves Social Functioning & Life Engagement For People With Schizophrenia

The newly approved antipsychotic medication Cobenfy, in addition to reducing core symptoms of schizophrenia in adults, also improves social functioning and life engagement, compared to a placebo. The higher level of life engagement manifested as improved motivation and social interaction.

COBENFY™ (xanomeline and trospium chloride), formerly KarXT, is used to treat adults diagnosed with schizophrenia. It was approved by the U.S. Food and Drug Administration (FDA) on September 26, 2024. The medication was developed by Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March 2024. In clinical trials, people who took Cobenfy had reductions in symptoms . . .